Why the study?
Does neutralizing anti-VEGF monoclonal antibody treatment prevent hyperglycemia-induced structural and functional microvascular alterations in the peritoneal membrane of streptozotocin-induced diabetic rats?
Population
Streptozotocin-induced diabetic rats and age-matched controls
Comparison
Long-term treatment with neutralizing anti-VEGF… vs Isotype-matched control antibodies
Design
Preclinical
Follow-up
Long-term
Authors
Loading...
Identifies VEGF as a modifiable mediator of peritoneal microvascular damage in diabetes; leaves open translation to patients on peritoneal dialysis.
Does neutralizing anti-VEGF monoclonal antibody treatment prevent hyperglycemia-induced structural and functional microvascular alterations in the peritoneal membrane of streptozotocin-induced diabetic rats?
VEGF blockade prevents hyperglycemia-induced peritoneal microvascular dysfunction in diabetic rats, suggesting a causative link between high glucose, VEGF upregulation, and peritoneal membrane alterations.
Vriese et al. (2001) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: